Company: LENZ
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001815776-25-000032
Chunk: 306

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 306
---
 cash equivalents and marketable securities as of the dates presented (in thousands):March 31, 2025Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesEstimated FairValueCash equivalents:Money market funds$21,973 $— $— $21,973 Corporate debt securities646 1 — 647 Marketable securities:Commercial paper$51,926 $24 $(17)$51,933 U.S. treasury securities48,785 66 — 48,851 Corporate debt securities44,898 33 (3)44,928 U.S. government agency securities25,203 21 (2)25,222 Totals$193,431 $145 $(22)$193,554 

13

December 31, 2024Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesEstimated FairValueCash equivalents:Money market funds$17,693 $— $— $17,693 U.S. government securities999 — — 999 U.S. treasury securities997 — — 997 Marketable securities:Commercial paper$58,798 $56 $(31)$58,823 U.S. treasury securities46,231 80 (2)46,309 Corporate debt securities43,634 49 (14)43,669 U.S. government agency securities40,013 60 (2)40,071 Totals$208,365 $245 $(49)$208,561 The following table presents available-for-sale securities by contractual maturity date as of March 31, 2025 (in thousands):March 31, 2025Amortized CostEstimated Fair ValueDue in one year or less$155,391 $155,475 Due after one year15,421 15,459 Total$170,812 $170,934 As of March 31, 2025, twenty-four of the Company's marketable securities with a fair market value of $30.5 million were in an immaterial aggregate gross unrealized loss position; these twenty-four marketable securities have all been in a gross unrealized loss position for less than one year. Based on a review of these marketable securities, the Company believes none of the unrealized loss is the result of a credit loss as of March 31, 202